ArticleDrug design, development and therapy2014

Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway.

Tao Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.